Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








ACIP Evidence to Recommendations for use of PreHevbrio Hepatitis B (HepB) Vaccine in Adults						Print
																Related Pages
										**Question:** Should PreHevbrio be recommended as an option for adults recommended for hepatitis B (HepB) vaccination?
**Population:** Adults greater than or equal to 18 years of age
**Intervention:** PreHevbrio – 3 doses over 6 months
**Comparison(s):** Existing HepB vaccines licensed for adults in the US (Twinrix, Engerix-B, Recombivax-HB, Heplisav-B)*
**Outcomes:**
Hepatitis B virus (HBV) infection (CRITICAL)
Serious adverse events (CRITICAL)
Mild adverse events (IMPORTANT but not critical)
*Of the adult HepB vaccines licensed in the United States, the included studies had only **Engerix-B** as a comparator**Background:**On November 3, 2021, ACIP voted to recommend universal adult HepB vaccination for all adults aged 19 through 59 years. Prior to the February 23, 2022 ACIP meeting, four HepB vaccines were recommended for use by ACIP (Engerix-B, Recombivax-HB, Twinrix, Heplisav-B). FDA approval for PreHevbrio was completed on November 30, 2021. Safety and immunogenicity data for PreHevbrio was presented by the vaccine manufacturer (VBI Vaccines, Delaware, USA), to ACIP on January 12, 2022.
The purpose of this EtR was to consider the addition of a new 3-antigen HepB vaccine candidate (PreHevbrio) as an option for prevention of hepatitis B on the CDC adult immunization schedule (starting in 2023). Based on key similarities with the approved single-antigen adult HepB vaccines, including immunogenicity, dosing schedule, mechanism, and safety profile, no ACIP vote was required for this action, and the EtR Framework was presented as an informational session on February 23, 2022.
Note: the safety and effectiveness of PreHevbrio have not been established in adults on hemodialysis. In addition, there are no adequate and well-controlled studies of PreHevbrio in pregnant women. Available human data on PreHevbrio administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Persons on hemodialysis, pregnant persons and persons who are breastfeeding are not discussed in the Evidence to Recommendations Framework.
*Additional background information supporting the ACIP recommendations on the use of PreHevbrio vaccine can be found in the relevant publication of the recommendation referenced on the**ACIP website**.*Problem
Problem
Criteria
Work Group Judgements
Evidence
Additional Information**Is the problem of public health importance?**
(Is the prevention of hepatitis B a problem of public health importance?)
**Yes**
In 2021, ACIP approved universal HepB vaccine recommendations for adults ages 19 through 59 years.
An additional HepB vaccine that is safe and non-inferior to existing ACIP-approved HepB vaccines could be a beneficial adjunct in achieving HHS goals of eliminating hepatitis B as a public health threat in the United States by 2030.Benefits and Harms*

Benefits and Harms
Criteria
Work Group Judgements
Evidence
Additional Information**How substantial are the desirable anticipated effects?**
For prevention of HBV infection (seroprotection), how substantially different are the desirable anticipated effects of PreHevbrio compared with Engerix-B?
**Minimal**
The evidence suggests that seroprotection conferred by PreHevbrio is non-inferior (little or no difference) compared with seroprotection conferred by Engerix-B.**How substantial are the undesirable anticipated effects?**
For the outcomes of serious and mild adverse events, how substantially different are the undesirable anticipated effects of PreHevbrio compared with Engerix-B?
**Minimal**
PreHevbrio may result in little to no difference in serious adverse events when compared with serious adverse events resulting from Engerix-B.
PreHevbrio may result in little to no difference in mild adverse events when compared with mild adverse events resulting from Engerix-B.**Do the desirable effects outweigh the undesirable effects?**
Does the balance between desirable effects and undesirable effects favor PreHevbrio or Engerix-B?
**Favors both**
See GRADE Tables**What is the overall certainty of this evidence for the critical outcomes?**
**Probably not important uncertainty**
See GRADE Tables* Assumption: non-inferiority is equivalent among currently U.S.-recommended 3-dose HepB vaccines for the population of interest, since all currently recommended HepB vaccines have undergone ACIP review.Equity
Equity
Criteria
Work Group Judgements
Evidence
Additional Information**What would be the impact on health equity?**
What would be the impact of the PreHevbrio compared to Engerix-B on health equity?
**Probably no impact**
PreHevbrio provides an additional option to existing approved adult HepB vaccines.Based on similarities of dosage schedule, adjuvant, and vaccine mechanism, ACIP Hepatitis Work Group perceived that the domains of Values, Acceptability, Resource Use, and Feasibility for PreHevbrio are comparable with Values, Acceptability, Resource Use and Feasibility of Engerix-B.
Balance of consequences
Desirable consequences clearly outweigh undesirable consequences in most settings.
Recommendation
PreHevbrio may be used as a HepB vaccine in persons aged ≥18 years recommended for vaccination against HBV infection.
Additional Considerations
Persons on hemodialysis, pregnant persons and persons who are breastfeeding are not discussed in this Evidence to Recommendations Framework. The safety and effectiveness of PreHevbrio have not been established in adults on hemodialysis. There are no adequate and well-controlled studies of PreHevbrio in pregnant women. Available human data on PreHevbrio administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of PreHevbrio on the breastfed infant or on milk production/excretion.References
Vesikari T, Langley JM, Segall N, et. al. Immunogenicity and safety of a tri-antigenic hepatitis B vaccine, Sci-B-Vac®, compared with a mono-antigenic HepB vaccine, Engerix-B®, in adults: The PROTECT randomized clinical trial. The Lancet Infectious Diseases. 2021.
Vesikari T, Finn A, van Damme P, et al. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Network Open. 2021; 4(10).
Diaz-Mitoma F, Popovic V, Spaans JN. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial. Vaccine. 2021 Jun 29;39(29):3892-3899. Epub 2021 Jun 8.
Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Isr Med Assoc J. 2001 May;3(5):328-32.
Esaulenko EV, Yakovlev AA, Volkov GA, et. al. Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation. Clin Infect Dis. 2021 Nov 2;73(9).
Etzion O, Novack V, Perl Y, et. al. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial. J Crohns Colitis. 2016 Aug;10(8):905-12. Epub 2016 Feb 29.
Yap I, Guan R, Chan SH. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol. 1995 Jan-Feb;10(1):51-5.
Murthy N, Wodi AP, Bernstein H, McNally V, Cineas S, Ault K. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:229–233.
GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2021. Available from gradepro.org.
Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.Top of Page
							
					
							Last Reviewed:  March 30, 2022						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue